Nan Fung Trinity’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nan Fung Trinity’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.5M	Buy	+450,000	New	+$4.07M	0.44%	50

Other funds holding BCRX

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Counterweight Ventures Wilmington, North Carolina $201M AUM 35.56% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Nan Fung Trinity's BCRX Position: Q2 2026 in Review

Nan Fung Trinity opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 450,000 shares worth $4.5M. The stake represents 0.44% of the portfolio and ranks #50 among its holdings.

40 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Nan Fung Trinity held 450,000 shares of BioCryst Pharmaceuticals worth $4.5M as of Q2 2026.
BioCryst Pharmaceuticals was a new Nan Fung Trinity position in Q2 2026.
BioCryst Pharmaceuticals made up 0.44% of Nan Fung Trinity's portfolio in Q2 2026, its #50 holding.
40 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Nan Fung Trinity's 13F filing for Q2 2026, filed 24 Jul 2026.